Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Sonoma Pharmaceuticals (SNOA) Capital Leases (2017 - 2018)

Sonoma Pharmaceuticals has reported Capital Leases over the past 2 years, most recently at $62000.0 for Q3 2018.

For Q3 2018, Capital Leases fell 71.69% year-over-year to $62000.0; the TTM value through Sep 2018 reached $62000.0, down 71.69%, while the annual FY2018 figure was $144000.0, 14.29% down from the prior year.
Capital Leases for Q3 2018 was $62000.0 at Sonoma Pharmaceuticals, down from $104000.0 in the prior quarter.
Over five years, Capital Leases peaked at $252000.0 in Q2 2017 and troughed at $62000.0 in Q3 2018.